Skip to main content

Graf James A's Form 4 filing

NKGen Biotech, Inc. (NKGN) · filed Dec 5, 2023

Accession no.
0001209191-23-057369
Filed
Dec 5, 2023, 3:50 PM ET
Trade date
Dec 1-4, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $2.17K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Graf James ACIK 0001519672Officer (Interim CFO)
Graf Acquisition Partners IV LLCCIK 000186262210% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2023Common StockPPurchaseAcquired+220$3.35F1+$737243Direct
Dec 4, 2023Common StockPPurchaseAcquired+450$3.19F2+$1,435.5693Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.31 to $3.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.03 to $3.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)